Literature DB >> 27044773

Intraductal malignant tumors in the liver mimicking cholangiocarcinoma: Imaging features for differential diagnosis.

Ah Yeong Kim1, Woo Kyoung Jeong1.   

Abstract

Entities:  

Keywords:  Bile duct tumor; Gadoxetic acid-enhanced MRI; Intrabiliary metastasis; Intraductal growing hepatocellular carcinoma

Mesh:

Year:  2016        PMID: 27044773      PMCID: PMC4825168          DOI: 10.3350/cmh.2016.22.1.192

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN: 2287-2728


× No keyword cloud information.

INTRODUCTION

The spectrum of bile duct lesions ranges from benign tumors, such as adenomas, papillomas, villous tumors and leiomyomas, to malignant lesions, such as invasive intraductal papillary neoplasm of the bile duct (IPNB) and intraductal cholangiocarcinomas. Bile duct tumors cause bile duct obstruction with biliary stasis and consequent symptoms such as jaundice, itching, weight loss and abdominal pain. Although diagnostic accuracy of imaging technique for bile duct tumors has been improved including computed tomography (CT), magnetic resonance imaging (MRI) and MR cholangiopancreaticography (MRCP), accurate differential diagnosis is sometimes difficult in real clinical practice. Hepatocellular carcinoma with bile duct invasion or intraductal growth of liver metastasis is a very rare disease, but accurate imaging diagnosis is important because misdiagnosis can result in wrong treatment strategy and can cause serious problem of patient-doctor relationship. Thus, to avoid such a tragedy, doctors should guess the variable differential diagnoses of bile duct malignancies which seems to be like intrahepatic cholangiocarcinoma. Herein, we report two rare cases of bile duct tumors.

CASE REPORT

Case 1

A 43-year-old male patient underwent total colectomy for multiple carcinomas in ascending and transverse colon, followed by adjuvant chemotherapy. According to the pathologic report, the pathologic T stage was T2 and T1, for ascending and transverse colon cancer, respectively and N stage was N1c, and tumors showed mucin production (10 %). There was no evidence of other organ metastasis on the initial imaging work up. However, two years later, segmental intrahepatic bile duct dilatation in liver segment 2 (S2) was depicted on the postoperative follow up abdominal computed tomography (CT) scan and there was 4 cm low density mass lesion around the dilated bile duct at the S2 periphery (Fig. 1). For further workup, Gadoxetic acid-enhanced pancreas magnetic resonance imaging (MRI) was performed. We again noted dilated bile duct in S2 with peripheral mass formation (Fig. 2). Within the dilated bile duct, intraductal lesion which showed high signal intensity (SI) on T2-weighted images (T2WI) and low SI on T1-weighted images (T1WI) was identified. After contrast administration, both the intraductal lesion and the peripheral mass did not show avid arterial enhancement and persistent low SI on the delayed phase. The mass demonstrated high SI on diffusion-weighted images (DWI) and low apparent diffusion coefficient (ADC) value. The serum tumor marker, carbohydrate antigen (CA) 19-9 was elevated up to 310.61 U/mL, and carcino-embryonic antigen (CEA) was 15.06 ng/mL. Our first impression was invasive intraductal papillary neoplasm of the bile duct (IPNB), however intraductal metastasis from colon cancer was also considered. He underwent left lateral segmentectomy. However, the histologic diagnosis was metastatic adenocarcinoma from colon with exuberant mucin production and extensive necrosis (40%).
Figure 1.

Segmental intrahepatic bile duct dilatation (white arrows on A, C) with low density mass lesion around the dilated bile duct at liver S2 (white arrowhead on B) on the abdominal CT scan. CT, computed tomography.

Figure 2.

On MRI, intraductal lesion (white arrows) and periductal mass (white arrowheads) show high SI on T2WI (A), and low SI on T1WI (B). There is no avid enhancement on arterial phase images (C) and persistent low SI on delayed phase images (D). The lesion demonstrates diffusion restriction (E, F). After left lateral segmentectomy, this lesion was proven to be metastatic adenocarcinoma from colon. MRI, magnetic resonance imaging; SI, signal intensity; T2WI, T2-weighted images; T1WI, T1-weighted images.

Case 2

A 55-year-old male patient was referred to our hospital for evaluation of a hepatic tumor. The patient had alcoholic liver disease, and symptoms including jaundice and itching sense had been developed one week ago. Liver function tests showed normal range of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). The serum tumor marker, α-fetoprotein (AFP) was also normal range. However, CA 19-9 was elevated up to 465.85 U/mL. There was an intraluminal growing polypoid enhancing mass at the primary confluence of bile duct, extending to the second order branch of right intrahepatic bile duct on CT scan (Fig. 3A). On MRI, this lesion depicted as high SI on T2WI, and low SI on T1WI. After, contrast administration, it showed arterial enhancement. It showed washout on portal and delayed phase. And low SI on hepatobiliary phase, and definite diffusion restriction (Fig. 3B-H). This lesion caused biliary obstruction, resulted in peripheral intrahepatic bile duct dilatation. And the serum total bilirubin level was 17.2 mL/dL, and direct bilirubin was 12.9 mL/dL. Our impression was intraluminal growing hilar cholangiocarcinoma. The patient underwent right hemihepatectomy and caudate lobectomy. However, the histopathologic diagnosis was intraductal growing hepatocellular carcinoma (HCC), confined to the bile duct wall.
Figure 3.

Intraductal growing polypoid enhancing mass (white arrows) at the proximal bile duct with peripheral intrahepatic bile duct dilatation (white arrowheads) on CT scan (A). On MRI, lesion shows high SI on T2WI (B), and low SI on T1WI (C). It shows arterial enhancement (D), low SI on delayed and hepatobiliary phase (E, F), and diffusion restriction (G, H). Right hemihepatectomy and caudate lobectomy was done, and the histopathologic diagnosis was intraductal growing HCC. CT, computed tomography; MRI, magnetic resonance imaging; SI, signal intensity; T2WI, T2-weighted images; T1WI, T1-weighted images; HCC, hepatocellular carcinoma.

DISCUSSION

Intrabiliary metastases

Morphologically, the gross appearance of liver metastases from colorectal carcinoma usually form as nodular or round masses, whereas intrabiliary growth in the bile duct is a rare manifestation [1,2]. Primary tumors that metastasize to the bile ducts include cancers of the lung, breast, gallbladder, colon, testicle, prostate, or pancreas; melanoma; and lymphoma. Of the listed cancers, colon adenocarcinoma, on account of its proclivity to spread along epithelial surfaces, shows a higher predilection to involve the biliary ducts [1]. The mechanism of intrabiliary metastasis of colon cancer is unclear; however, possible mechanisms include vascular invasion via the lymph vessels, blood vessels, or biliary tract, and implantation of malignant cells to the bile duct epithelium via the bile stream [3]. Imaging findings of metastases that show intrabiliary growth may mimic cholangiocarcinoma or IPNB [1,4-6]. When an intraductal lesion was detected, the following findings were found to be suggestive of intraductal metastasis, rather than intraductal cholangiocarcinoma: colorectal cancer as the extra-biliary malignant disease, a parenchymal mass that was contiguous with the intraductal lesion, and expansile growth of the intraductal lesion [7]. According to the previous report, usually, intraductal metastasis exhibits expansile intraluminal extension, but intraductal cholangiocarcinoma exhibits intraepithelial extension with a papillary growth pattern, due to its origination from the underlying papilloma or adenoma [7]. However, there are no reliable imaging features for distinction of biliary metastases from cholangiocarcinomas or IPNBs [8]; therefore, diagnosis is based solely on history and histologic findings. Immunohistochemical staining using cytokeratin (CK)-7 and CK-20 and mucin is necessary to differentiate between metastatic lesion arising from a colon carcinoma and cholangiocarcinoma or IPNB; metastatic colon carcinoma shows CK20 positivity and CK7 negativity in contradistinction to the adjacent bile duct epithelium, which is CK7 positive and CK20 negative [9]. In short, we should take metastatic lesions into consideration, when an intraductal lesion is found in a patient with colorectal malignancy, or a history of colorectal surgery.

Intraductal growing hepatocellular carcinoma

Hepatocellular carcinoma is the most common primary malignant hepatic neoplasm and rarely may show biliary ductal growth or invasion, as previously reported incidence of 1.2-9% [10,11]. These types have been classified as icteric type HCC by Lin et al. [12]. These tumors may manifest obstructive jaundice as the initial complaint [13]. Identification of this group of patients is clinically important, because surgical treatment may be beneficial. However, accurate preoperative diagnosis is difficult owing to the low prevalence of this pattern of growth and the nonspecific imaging findings. The imaging finding of HCC with an intraductal growth pattern appears as expansile soft tissue masses that cause dilatation of the bile duct [13]. According to the previous report, significant variables that help to differentiate HCC with intraductal growth from intraductal cholangiocarcinoma include the presence of parenchymal mass, liver cirrhosis, and a hyperattenuating intraductal tumor on the hepatic arterial phase [14]. The presented case in this report, intraductal tumor shows hyperenhancement on the arterial phase and washout on the portal venous phase compared to the liver parenchyma. Clinical and laboratory data such as the presence of predisposing factors for cirrhosis such as positive serologic results for hepatitis B or C and high serum levels of AFP may help to suggest the diagnosis of HCC.

SUMMARY

Despite remarkable recent improvements in the imaging tools for diagnosis of liver lesions, rare bile duct tumors are sometimes incorrectly diagnosed as cholangiocarcinoma or IPNB. To diagnose correctly and lead to proper treatment option, doctors should be familiar with the clinical manifestation and the imaging findings of rare bile duct tumors such as intraductal metastasis or intraductal growing HCC as well as more common tumors such as cholangiocarcinoma.
  14 in total

1.  Icteric type hepatoma.

Authors:  T Y Lin; K M Chen; Y R Chen; W S Lin; T H Wang; J L Sung
Journal:  Med Chir Dig       Date:  1975

2.  Computed tomography features of an intraductal polypoid mass: differentiation between hepatocellular carcinoma with bile duct tumor invasion and intraductal papillary cholangiocarcinoma.

Authors:  Ah Young Jung; Jeong Min Lee; Seung Hong Choi; Se Hyung Kim; Jae Young Lee; Sun-Whe Kim; Joon Koo Han; Byung Ihn Choi
Journal:  J Comput Assist Tomogr       Date:  2006 Jan-Feb       Impact factor: 1.826

3.  Early hepatocellular carcinoma presenting with biliary ductal invasion--a case report.

Authors:  J W Leong; J M Ho; H S Ng; J P Raj
Journal:  Ann Acad Med Singapore       Date:  2000-01       Impact factor: 2.473

4.  Intrabiliary growth of metastatic colonic adenocarcinoma: a pattern of intrahepatic spread easily confused with primary neoplasia of the biliary tract.

Authors:  M A Riopel; D S Klimstra; C V Godellas; L H Blumgart; W H Westra
Journal:  Am J Surg Pathol       Date:  1997-09       Impact factor: 6.394

5.  Intraductal papillary growth of liver metastasis originating from colon carcinoma in the bile duct: report of a case.

Authors:  Atsushi Nanashima; Syuuichi Tobinaga; Masato Araki; Masaki Kunizaki; Kuniko Abe; Hideyuki Hayashi; Kenichi Harada; Yasuni Nakanuma; Tohru Nakagoe; Hiroaki Takeshita; Terumitsu Sawai; Takeshi Nagayasu
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

6.  A new macroscopic classification predicts prognosis for patient with liver metastases from colorectal cancer.

Authors:  K Yasui; T Hirai; T Kato; A Torii; K Uesaka; T Morimoto; Y Kodera; Y Yamamura; T Kito; N Hamajima
Journal:  Ann Surg       Date:  1997-11       Impact factor: 12.969

7.  Macroscopic intrabiliary growth of liver metastases from colorectal cancer.

Authors:  K Okano; J Yamamoto; Y Moriya; T Akasu; T Kosuge; M Sakamoto; S Hirohashi
Journal:  Surgery       Date:  1999-11       Impact factor: 3.982

8.  Liver metastasis from rectal cancer with prominent intrabile duct growth.

Authors:  Susumu Takamatsu; Kenichi Teramoto; Tohru Kawamura; Atsushi Kudo; Norio Noguchi; Takumi Irie; Takanori Ochiai; Jiro Kumagai; Morio Koike; Shigeki Arii
Journal:  Pathol Int       Date:  2004-06       Impact factor: 2.534

9.  Hepatocellular carcinoma presenting as intrabile duct tumor growth: a clinicopathologic study of 24 cases.

Authors:  M Kojiro; K Kawabata; Y Kawano; F Shirai; N Takemoto; T Nakashima
Journal:  Cancer       Date:  1982-05-15       Impact factor: 6.860

10.  Colon cancer metastasis mimicking intraductal papillary neoplasm of the extra-hepatic bile duct.

Authors:  Takanobu Yamao; Hiromitsu Hayashi; Takaaki Higashi; Hideyuki Takeyama; Takayoshi Kaida; Hidetoshi Nitta; Daisuke Hashimoto; Akira Chikamoto; Toru Beppu; Hideo Baba
Journal:  Int J Surg Case Rep       Date:  2015-03-13
View more
  3 in total

Review 1.  Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.

Authors:  Jae Hyun Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

2.  Extraction of intra-biliary hepatocellular carcinoma by endoscopic retrograde cholangiopancreatography.

Authors:  Chieh Sian Koo; Khek Yu Ho; Yin Huei Pang; Daniel Q Huang
Journal:  BMC Gastroenterol       Date:  2020-12-07       Impact factor: 3.067

3.  Diagnosing rare intraductal biliary neoplasms - Intraductal papillary neoplasm of the bile duct: A case report with typical imaging findings.

Authors:  Saumya Pandey; Nitin Agarwal; Vidushi Gupta; Ashok Sharma; Anil Aggarwal; Sunita Gupta; Ram Krishan
Journal:  SA J Radiol       Date:  2022-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.